The overall incidence of hypoglycemia was considerable in this large working-age population and was associated with $52 million (2008 dollars) in direct medical costs.
To estimate the rate and costs of hypoglycemia in patients with type 2 diabetes.
We used a retrospective cohort design to assess the rate and costs of hypoglycemia among working-age patients with type 2 diabetes in the 2004 to 2008 MarketScan database. Methods: We followed patients from cohort entry to the first instance of hypoglycemia requiring medical intervention (inpatient, emergency department [ED], or outpatient) and calculated incidence rates (IRs), stratifying these estimates by age (18-34, 35-49, 50-64, and 65 years) and gender. We calculated inflation-adjusted total and mean direct costs of medical visits for hypoglycemia, other diabetes-related visits, and all other medical visits.
The cohort was composed of 536,581 members with approximately 1.21 million person-years (p-yrs) of follow-up. The IR of hypoglycemic events leading to an inpatient admission, ED, or outpatient visit was 153.8/10,000 p-yrs. The IRs of hypoglycemic events were highest in adults aged 18 to 34 years (218.8/10,000 p-yrs). Regardless of age group, rates of hypoglycemia were greater in women than in men (P <.001). Total hypoglycemia costs were $52,223,675 over the study period and accounted for 1.0% of all inpatient costs, 2.7% of ED costs, and 0.3% of outpatient costs. The mean costs for hypoglycemia visits were $17,564 for an inpatient admission, $1387 for an ED visit, and $394 for an outpatient visit.
The overall incidence of visits for hypoglycemia was considerable in this large database, and was associated with high per-episode costs. Continued vigilance and the development of strategies to decrease potentially avoidable hypoglycemic episodes requiring medical intervention are needed.
(Am J Manag Care. 2011;17(10):673-680)
Our analyses evaluate the incidence and costs of hypoglycemia in a large working-age population with type 2 diabetes.
Hypoglycemia can occur during therapy with antidiabetic drug agents and has the potential to lead to serious complications, including morbidity and mortality. While these agents are effective in treating hyperglycemia, optimal glycemic control can be more difficult to attain. The risk of hypoglycemia remains a serious adverse effect of diabetic pharmacotherapy and a potential limit to aggressive treatment.
While hypoglycemia has been well-researched in patients with type 1 diabetes, previous studies in persons with type 2 diabetes have focused on populations with limited demographics,1-3 persons using insulin in type 2 diabetes,4 or specific oral medications,5 or were conducted outside of the United States.6 Furthermore, the incidence of hypoglycemia is often measured in clinical trials and may not approximate true rates in more real-world populations. Published incidence rates (IRs) of hypoglycemia in type 2 diabetes vary from 0.02 to 0.35 events/patient/year, but differences in study design, sample populations, and definitions of hypoglycemia make direct comparisons between studies problematic.7
Research indicates that hypoglycemia places an economic burden on healthcare payers, but estimates of the magnitude of that burden differ considerably. While several non-US—based cost studies of hypoglycemia have been published, broad differences in payer systems make these analyses less generalizable to the US healthcare system.8-12 Over the past 10 years, several US studies have evaluated the medical costs of hypoglycemia.13-15 Curkendall et al evaluated costs associated with development of hypoglycemia during an inpatient hospital stay,13 while Rhoads et al evaluated the costs of hypoglycemia in patients taking insulin.14 An additional study by Pelletier and colleagues15 assessed allowed health plan costs in a large sample of patients with type 2 diabetes who experienced at least 1 diabetes-related medical complication during the study. Within this study, 0.2% of the population had a hypoglycemic event in the first year, with a mean annual allowed charge for hypoglycemia of $345 (2007 US dollars). While several studies have assessed costs associated with hypoglycemia, none have comprehensively evaluated these costs in a population of patients with type 2 diabetes taking oral antidiabetic drugs (OADs).
While 1 in 10 US adults currently have diabetes, the Centers for Disease Control and Prevention estimate that 1 in 3 adults will have the disease by 2050.16 The management of diabetes complications such as hypoglycemia and resulting costs to the healthcare system will be of greater concern in upcoming years, and comprehensive analyses areneeded to measure hypoglycemia in the US population. Our objectives in this study were: 1) to estimate the incidence of hypoglycemia in a large sample of working-age patients with type 2 diabetes; and 2) to estimate the corresponding direct medical costs of hypoglycemia.
RESEARCH DESIGN AND METHODS
The data source was the Medstat MarketScan database, including pharmacy and medical (inpatient and outpatient) claims data for the years 2004 to 2008. The Medstat MarketScan database comprises more than 4 billion patient records, 69 million covered lives, 77 contributing employers, and 12 contributing heath plans.17 The Medstat MarketScan database compiles claims from work-based insurance plans including data from currently enrolled employees, early retirees, former employees covered by COBRA, and their dependents.18 Unlike many healthcare databases, the MarketScan database provides a near-complete capture of a member’s healthcare as it contains information on inpatient and outpatient medical visits, pharmacy claims, and carved-out services.18
We conducted a retrospective cohort study of patients with type 2 diabetes and identified all persons with 2 or more inpatient and/or outpatient claims for diabetes (International Classification of Diseases [ICD]-9 250.XX) during the study period. As hypoglycemia may be the result of diabetes medications, we excluded from this eligible sample persons who were not taking at least 1 OAD. We further excluded participants who did not have at least 12 months of continuous eligibility within a noncapitated health plan following the first fill date of an OAD. Finally, we excluded persons with at least 1 medical claim (inpatient or outpatient) for type 1 (ICD-9 250.X1 or 250.X3) or gestational diabetes (648.0X) during the study period.
For each cohort member, we initiated follow-up on the first date of fill for an OAD agent and identified the first lapse in continuous eligibility beyond the initial 12 months of eligibility used for sample identification. The last day of the month preceding the first gap in coverage served as the end of follow-up for each member. We characterized the study population by describing the demographics and estimated the prevalence of antidiabetic medication use, and micro- and macrovascular complications of diabetes. To identify medications taken within 90 days of cohort entry, we evaluated pharmacy claims for prescription fills of oral and injectable antidiabetic agents. To estimate the baseline prevalence of diabetes-related complications, we used methods employed in other studies,19 and assessed inpatient and outpatient medical claims within 90 days of cohort entry.
Hypoglycemic Event Characterization
We followed all cohort patients from their respective index dates to the end of their follow-up to identify instances of hypoglycemia requiring medical intervention (inpatient, emergency department [ED], and/or outpatient). To identify hypoglycemic episodes, we used the algorithm proposed by Ginde and colleagues.20 We identified the inpatient and outpatient claims for hypoglycemia using ICD-9 codes: 251.0, 251.1, 251.2, 270.3, and 962.3. In addition, we identified claims for ICD-9 code 250.8 in the absence of other contributing diagnoses (ICD-9 259.8, 272.7, 681.XX, 682.XX, 686.9X, 707.1-707.9, 709.3, 730.0-730.2, or 731.8). Our primary end point was the first medical encounter for hypoglycemia (inpatient, emergency department, or outpatient). We repeated similar procedures to look at the incidence for each of the 3 settings separately: the first inpatient admission, the first ED visit, or the first outpatient visit.
Cost Analyses Estimation
To estimate the direct medical costs associated with hypoglycemic events, we used the total gross payment to all providers associated with an admission in the inpatient claims database and the total gross payment to a provider for a specific service in the outpatient claims database. The cost estimates included all payments made to the provider by the patient including copayments, coinsurance, and deductibles. In addition to overall measures of cost, we calculated costs for 3 mutually exclusive groups of claims for all cohort members: 1) those related to hypoglycemia (identified using the Ginde algorithm20); 2) other diabetes-related claims (primary ICD-9 250.XX); and 3) all other claims. To capture episodes of care in the outpatient and ED settings, we summed costs associated occurwith claims on the same service date as 1 episode of care. The MarketScan data already provide summary costs associated with a particular inpatient admission within the database.18 In instances where ED visits resulted in inpatient hospitalization, the collective costs for both the ED visit and the resulting inpatient hospitalization were captured within the inpatient hospitalization. All cost variables from inpatient, ED, and outpatient claims were inflated to 2008 equivalents using the regional Consumer Price Index medical care expenditure category to allow for a proper comparison of costs across years.21 Lastly, we calculated per-member-per-month (PMPM) costs by dividing total costs for each category of care by the number of person-months in the study sample.
To describe the baseline characteristics of our study sample, we calculated frequencies for categorical variables and means for continuous covariates. To estimate the incidence of hypoglycemia resulting in an inpatient admission, ED, or outpatient visit, we conducted descriptive analyses. For each eligible member, we estimated person-years (p-yrs) of follow-up as the interval from the participant’s index date to the date of the first of the following events: a hypoglycemic episode; the end of continuous eligibility; or December 31, 2008. We calculated the IR by dividing the number of hypoglycemic events by the total p-yrs of follow-up and constructed 95% confidence intervals (CIs) around the estimated IRs. The final IRs and corresponding 95% CI are presented per 10,000 p-yrs. We further stratified these estimates by age (18-34, 35-49, 50-64, or 65 years), gender, and age and gender. Unadjusted Poisson regression models were used to conduct between-group comparisons of IRs (across age and gender) and t tests were calculated to compare mean total gross payments across cost categories (eg, hypoglycemia-related encounters, other diabetes-related encounters, and all other encounters). All analyses were performed using SAS Software (version 9.2; SAS Institute Inc, Cary, North Carolina).
Within the database, there were 2,913,422 persons with inpatient and/or outpatient claims for diabetes during 2004 to 2008. Of these, 2,629,476 (93.3%) had 2 or more claims for diabetes during the study period. We then excluded 1,302,342 persons (49.5%) who were not taking at least 1 OAD; 663,424 participants (25.2%) who did not have at least 12 months of continuous eligibility within a non-capitated health plan following the first fill date of an OAD; and 127,129 persons (4.8%) with at least 1 medical claim (inpatient or outpatient) for type 1 or gestational diabetes (648.0X) during the study period. Our final sample for analyses was 536,581.
Demographic and Clinical Characteristics
As presented in , the largest percentage of the population was between the ages of 50 and 64 years (70.8%), with an additional 25.7% aged 35 to 49 years. Only 3.3% of the study population was between the ages of 18 and 34 years and 0.1% were >65 years of age. The population had a slightly greater percentage of men (53.9%) versus women (46.1%). Within 90 days of cohort entry, 51.3% of the population had only 1 class of antidiabetic medication filled (referred to as monotherapy) while 48.7% had prescription fills for more than 1 class of antidiabetic drug therapy in the same 90-day period (combination therapy). The most common classes of OADs were metformin (75.7%), sulfonylureas (42.3%), and thiazolidinediones (33.3%). Insulin use in addition to OAD use was relatively infrequent, such that only 6.0% of the study population had a prescription for insulin filled in the baseline 90-day period. Overall, 7.0% of the study population had at least 1 macrovascular complication and 4.3% had at least 1 microvascular complication of diabetes. The prevalence of individual micro- and macrovascular complications of diabetes was relatively rare in the study population at baseline (<1.0%), with the exception of coronary artery disease (4.9%) and retinopathy (2.1%).
Incidence of Hypoglycemia
Overall, 3.5% (n = 18,657) of the study sample had at least 1 inpatient, ED, or outpatient visit for hypoglycemia. In , the overall IR of a medical encounter for hypoglycemia was 153.8 per 10,000 p-yrs. The IR was highest in the youngest study members (18-34 years; 218.8 per 10,000 p-yrs) followed by the >65 year cohort members (193.2 per 10,000 p-yrs). The rate of hypoglycemia was higher for women (168.7 per 10,000 p-yrs) than for men (141.0 per 10,000 p-yrs; P <.001), a trend consistent across all age categories. Women 18 to 34 years of age had an IR of 267.0 per 10,000 p-yrs compared with an IR of 159.8 per 10,000 p-yrs in men of the same age (P <.001). Statistically significant differences in IR also occurred when comparing men and women in the 35 to 49 year age category (P <.001) and the 50 to 64 year age category (P <.001). Within the 65 year age category, the IR did not differ statistically between men and women (P = .833).
As presented in , the overall rate of inpatient admissions was relatively infrequent, with a rate of 13.5 per 10,000 p-yrs. ED visits were more frequent, with an IR of 32.8 per 10,000 p-yrs. Outpatient visits occurred at the greatest rate, with 118.9 outpatient hypoglycemic encounters occurring per 10,000 p-yrs. As with the composite measure, the incidence of hypoglycemia was typically higher in women than in men across all age groups and in all 3 settings.
Direct Medical Costs of Hypoglycemia
In , we present the results of the cost analyses. During the study period, costs associated with hypoglycemia visits were $52,223,675, or 0.6% of all inpatient, ED, or outpatient costs. Hypoglycemia visits accounted for 1.0% of all inpatient costs, 2.7% of ED costs, and 0.3% of outpatient costs during the study period. The mean cost for inpatient hypoglycemia admissions was $17,564.25, compared with $13,862.03 for other diabetes-related inpatient admissions (P <.001) and $19,146.25 for all other inpatient admissions (P = .026). The mean cost for an ED visit related to hypoglycemia was $1386.80 relative to $320.54 for other diabetes-related ED visits (P <.001) and $632.32 for all other ED visits (P <.001). Mean cost for an outpatient hypoglycemia-related episode ($393.64) was higher than the mean cost for other diabetes-related encounters ($112.22; P <.001) and for non—diabetes-related encounters ($380.15; P = .05) within the same setting. The sum of PMPM costs related to hypoglycemia and diabetes in all settings was $36.98; 9.7% of all diabetes costs ($3.58) were related to hypoglycemia treatment. PMPM costs for hypoglycemia were highest for inpatient admissions at $2.12, which was 40.7% of all inpatient PMPM costs for diabetes care and approximately 1% of all inpatient costs.
Our study is a large retrospective cohort study assessing the incidence and costs of hypoglycemia-related medical visits in persons with type 2 diabetes and taking at least 1 OAD. To our knowledge, our study is the first to assess the comprehensive incidence of hypoglycemia and direct medical costs in a large, real-world population of adults with type 2 diabetes. We found the risk of hypoglycemia requiring medical intervention to be 3.5%, with total costs in excess of $52 million (2008 dollars). Our comprehensive assessment of hypoglycemia-related medical visits highlights the continued need for vigilance regarding adverse events associated with OAD therapy.
While other studies reviewed here have assessed rates of serious hypoglycemic events, direct comparison to our estimates is difficult as the sampled populations, definitions of hypoglycemia, and settings studied vary widely. In our study of hypoglycemic events warranting a medical encounter, we found an overall rate of 153.8 per 10,000 p-yrs among patients with type 2 diabetes taking 1 or more OADs. First hypoglycemia-related outpatient encounters occurred approximately 10 times more frequently as first hypoglycemia-related inpatient encounters in this cohort. A recent cohort study in England found similar rates of hypoglycemia (as diagnosed and reported by study participant’s general practitioner) for nateglinide (15.71 per 1000 p-yrs) and repaglinide (20.32 per 1000 p-yrs) users, but somewhat lower rates for rosiglitazone (9.94 per 1000 p-yrs) and pioglitazone (9.64 per 1000 p-yrs) users.22 In a study of persons with type 2 diabetes, taking an oral agent with or without insulin using the General Practice Research Database (GPRD), the rate of mild/moderate (reported by general practitioner) or severe (requiring hospitalization) hypoglycemia was 60 per 100,000 p-yrs for sulfonylureas and 110 per 100,000 p-yrs for metformin with an overall risk for hypoglycemia in the study of 4.1%.23 In a 1-year prospective cohort study, 39% of sulfonylurea users reported at least 1 hypoglycemic event compared with 51% of new insulin users (<2 years) and 64% of persons using insulin for >5 years.24 Finally, 2 other studies assessed rates of hypoglycemia resulting in ED visits. In a 4-year (1997-2000) prospective study conducted in Germany, the highest rate of ED visits related to sulfonylurea use was in glibenclamide users (5.6 per 1000 p-yrs),25 a rate comparable to our estimated rate of first ED visit (32.8 per 10,000). However, the mean age of persons with hypoglycemic events in this study was 79 years,25 an age group not adequately represented in our cohort. A 12-year prospective study of ED visits in Switzerland in persons with type 2 diabetes using sulfonylureas found a lower rate of ED visits (0.92 per 1000 p-yrs).26 Our study presents a more comprehensive recent assessment of instances of hypoglycemia requiring medical intervention and therefore provides new insight into the considerable impact of hypoglycemia on the rate of utilization of medical visits in the United States.
Another study finding was the increased rate of hypoglycemia by younger (aged 18-34 years) and relatively older (aged 65 years) adults in our cohort, although the number of older adults and corresponding hypoglycemic events included in our cohort was small (n = 655 with 12 events). In a study by van Staa and colleagues using the GPRD, the overall rate of hypoglycemia in sulfonylurea users at least 65 years of age was 196.7 per 10,000 p-yrs,27 a rate comparable to cohort members aged at least 65 years in our study (193.2 per 10,000 p-yrs). An older study of Medicaid enrollees with type 2 diabetes estimated the rate of serious hypoglycemic events in sulfonylurea users at least 65 years of age to be 123.1 per 10,000 p-yrs.28 It should be noted, however, that these studies had a broader range of older adults, whereas our population was closer to 65 years of age. We are unaware of studies that assessed rates of hypoglycemia in young adults (18-29 years). Lastly, the van Staa study also demonstrated a higher rate of hypoglycemia in women as compared with men,27 a pattern that was found in our study across all age groups.
Our analyses indicate that while hypoglycemia is relatively infrequent in this large working-age population, the mean cost of medical encounters associated with hypoglycemia was up to 4 times higher than for other diabetes-related claims. Furthermore, the total costs of all hypoglycemia-related inpatient admissions exceeded the costs of all hypoglycemia-related ED and outpatient visits combined. Recently, Curkendall et al found that a diagnosis of hypoglycemia in the inpatient setting was associated with over 38% higher total charges than in patients without hypoglycemia.13 In the same study, mean total inpatient charges for patients with hypoglycemia were approximately $86,000, compared with approximately $54,000 for patients without the complication.13 A study by Pelletier and colleagues of more than 44,000 patients with type 2 diabetes, however, found that mean direct medical charges for hypoglycemia complications were approximately $454.15 This study reported that 12-month mean allowed amounts for hypoglycemia totaled $345, but this analysis did not distinguish costs by setting type.15 A 1999 to 2001 study using MarketScan data found that annualized hypoglycemia-related medical costs were $3241 for insulin users.29 The absolute direct cost of medical visits for hypoglycemia was $52 million within our sample, with potentially avoidable inpatient admissions for hypoglycemia accounting for nearly 60% of medical costs for hypoglycemia ($30,930,649 of $52,223,675). While per-episode costs were high, overall PMPM costs associated with hypoglycemia were relatively low. As hypoglycemic events are potentially avoidable, development of additional strategies to decrease rates of hypoglycemia that warrant medical intervention are necessary.
While our study provides several advantages over previous studies of hypoglycemia, there are several limitations that we must address. First, the data we used are from a large healthcare database, generally containing workplace-sponsored insurance plans, and therefore may not be generalizable to all persons with type 2 diabetes. Notably, within our study, 4.3% and 7.0% of patients had evidence of micro- and macrovascular complications of diabetes, respectively, within 90 days of cohort entry. Another study estimated the prevalence of macrovascular complications to be 28.1% and 20.2% for microvascular complications.30 Secondly, our analyses focused on 1 direct effect of hypoglycemic episodes—medical encounters. As a result, our study does not capture minor instances of hypoglycemia and therefore underestimates the true burden of hypoglycemia, including the resulting impact on morbidity, mortality, and indirect factors (eg, lost work or productivity). Lastly, we were unable to capture medical claims for hypoglycemia that might have occurred prior to the date of cohort entry. Therefore, the incidence of hypoglycemia calculated within our study represents the first event experienced by the patient during the time period of the study, not necessarily the first episode.
The overall rate of hypoglycemia requiring medical intervention was 153.8 hypoglycemic episodes per 10,000 p-yrs among patients with type 2 diabetes taking at least 1 OAD.The rate of hypoglycemia was highest in youngest (18-34 years) and older (65 years) patients and higher in women than men. The total costs associated with medical visits and hospitalizations for hypoglycemia were in excess of $52 million (2008 dollars; $30,930,649 for inpatient, $6,606,733 for ED, and $14,686,293 for outpatient visits). Further, the total costs of all hypoglycemia-related inpatient admissions exceeded the costs of all hypoglycemia-related ED and outpatient visits combined. Younger adults and women with type 2 dia-betes may require more assistance to prevent hypoglycemic episodes. Continued vigilance for the occurrence and costs of hypoglycemia in patients with type 2 diabetes is essential. As hypoglycemia remains an important barrier to medication treatment of type 2 diabetes, strategies to decrease the incidence of hypoglycemia are needed.
Author Affiliations: From College of Pharmacy (BJQ, JCS, ABO, SJK), University of Rhode Island, Kingston, RI.
Funding Source: This research was funded by a grant from Takeda Pharmaceuticals America, Inc.
Author Disclosures: Dr Quilliam reports consultancies or paid advisory boards from OMJ Scientific Affairs. He and Dr Simeone have received grants from Takeda Pharmaceuticals America, Inc, and both have received payment for involvement in the preparation of this manuscript as part of a grant study funded by Takeda. Dr Kogut has received grants from Takeda Pharmaceuticals. Dr Ozbay reports no relationship or financial interest with any entity thatwould pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (BJQ, JCS, ABO, SJK); acquisition of data (BJQ, SJK); analysis and interpretation of data (BJQ, JCS, ABO); drafting of the manuscript (BJQ, JCS); critical revision of the manuscript for important intellectual content (BJQ, JCS); statistical analysis (BJQ, JCS, ABO); obtaining funding (BJQ, SJK); and administrative, technical, or logistic support (SJK).
Address correspondence to: Brian J. Quilliam, PhD, College of Pharmacy, University of Rhode Island, 41 Lower College Rd, Kingston, RI 02881. E-mail: firstname.lastname@example.org.
1. Greco D, Pisciotta M, Gambina F, Maggio F. Severe hypoglycaemia leading to hospital admission in type 2 diabetic patients aged 80 years or older. Exp Clin Endocrinol Diabetes. 2010;118(4):215-219.
2. Gottschalk M, Danne T, Vlajnic A, Cara JF. Glimepiride versus metformin as monotherapy in pediatric patients with type 2 diabetes: a randomized, single-blind comparative study. Diabetes Care. 2007;30(4): 790-794.
3. Sugarman JR. Hypoglycemia associated hospitalizations in a population with a high prevalence of non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract. 1991;14(2):139-147.
4. Cox DJ, Gonder-Frederick L, Ritterband L, Clarke W, Kovatchev BP. Prediction of severe hypoglycemia. Diabetes Care. 2007;30(6): 1370-1373.
5. Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. Diabetes Obes Metab. 2007; 9(2):166-174.
6. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, Lyu R, Mavros P, Yin D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab. 2008;10(suppl 1):25-32.
7. Zammitt NN, Frier BM. Hypoglycemia in type 2 diabetes: pathophysiology, frequency, and effects of different treatment modalities. Diabetes Care. 2005;28(12):2948-2961.
8. Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26(4):1176-1180.
9. Hammer M, Lammert M, Mejias SM, Kern W, Frier BM. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281-290.
10. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care. 2002;25(11):2109-2110.
11. Jonsson L, Bolinder B, Lundkvist J. Cost of hypoglycemia in patients with Type 2 diabetes in Sweden. Value Health. 2006;9(3):193-198.
12. Lundkvist J, Berne C, Bolinder B, Jonsson L. The economic and quality of life impact of hypoglycemia. Eur J Health Econ. 2005;6(3): 197-202.
13. Curkendall SM, Natoli JL, Alexander CM, Nathanson BH, Haidar T, Dubois RW. Economic and clinical impact of inpatient diabetic hypoglycemia. Endocr Pract. 2009;15(4):302-312.
14. Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and shortterm disability in employees with diabetes. J Occup Environ Med. 2005;47(5):447-452.
15. Pelletier EM, Smith PJ, Boye KS, Misurski DA, Tunis SL, Minshall ME. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. Appl Health Econ Health Policy. 2008;6(2-3):103-112.
16. Boyle JP, Thompson TJ, Gregg EW, Barker LE, Williamson DF. Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence. Popul Health Metr. 2010;8(1):29.
17. Adamson DM, Chang S, Hansen LG. Health research data for the real world: the Marketscan databases. New York, NY: Thompson Healthcare; 2008.
18. MarketScan User Guide. Ann Arbor, MI: Thomson Reuters; 2007.
19. Meduru P, Helmer D, Rajan M, Tseng C, Pogach L, Sambamoorthi U. Chronic illness with complexity: implications for performance measurement of optimal glycemic control. J Gen Intern Med. 2007;22 (suppl 3):408-418.
20. Ginde AA, Blanc PG, Lieberman RM, Camargo CA Jr. Validation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits. BMC Endocr Disord. 2008;8:4.
21. Perrins G, Nilsen D. Math Calculations to Better Utilize CPI Data. Bureau of Labor Statistics. http://www.bls.gov/cpi/cpimathfs.pdf. Published 2007. Accessed September 20, 2011.
22. Vlckova V, Cornelius V, Kasliwal R, Wilton L, Shakir SA. Hypoglycaemia with oral antidiabetic drugs: results from prescription-event monitoring cohorts of rosiglitazone, pioglitazone, nateglinide andxrepaglinide. Drug Saf. 2009;32(5):409-418.
23. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Metformin, sulfonylureas, or other antidiabetes drugs and the risk of lactic acidosis or hypoglycemia: a nested case-control analysis. Diabetes Care. 2008;31(11):2086-2091.
24. Group UHS. Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration. Diabetologia. 2007; 50(6):1140-1147.
25. Holstein A, Plaschke A, Egberts EH. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev. 2001;17(6):467-473.
26. Stahl M, Berger W. Higher incidence of severe hypoglycaemia leading to hospital admission in Type 2 diabetic patients treated with longacting versus short-acting sulphonylureas. Diabet Med. 1999;16(7): 586-590.
27. van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol. 1997;50(6):735-741.
28. Shorr RI, Ray WA, Daugherty JR, Griffin MR. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc. 1996;44(7):751-755.
29. Rhoads GG, Orsini LS, Crown W, Wang S, Getahun D, Zhang Q. Contribution of hypoglycemia to medical care expenditures and shortterm disability in employees with diabetes. J Occup Environ Med. 2005;47(5):447-452.
30. Lin EH, Rutter CM, Katon W, et al. Depression and advanced complications of diabetes: a prospective cohort study. Diabetes Care. 2010;33(2):264-269.